BioNTech SE

BRSE:22UA Stock Report

Market Cap: CHF19.8b

BioNTech Valuation

Is 22UA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 22UA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 22UA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 22UA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 22UA?

Other financial metrics that can be useful for relative valuation.

22UA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.2x
Enterprise Value/EBITDA-244.1x
PEG Ratio8.6x

Price to Sales Ratio vs Peers

How does 22UA's PS Ratio compare to its peers?

The above table shows the PS ratio for 22UA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.1x
BSLN Basilea Pharmaceutica
3.3x8.7%CHF517.3m
SDZ Sandoz Group
1.5x4.6%CHF13.5b
IDIA Idorsia
2x23.0%CHF377.3m
LONN Lonza Group
5.7x9.6%CHF38.0b
22UA BioNTech
7.4x7.5%CHF21.7b

Price-To-Sales vs Peers: 22UA is expensive based on its Price-To-Sales Ratio (7.4x) compared to the peer average (3.1x).

Price to Earnings Ratio vs Industry

How does 22UA's PE Ratio compare vs other companies in the European Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a30.7%
 n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a30.7%
 n/an/an/a
No more companies

Price-To-Sales vs Industry: 22UA is good value based on its Price-To-Sales Ratio (7.4x) compared to the European Biotechs industry average (9.7x).

Price to Sales Ratio vs Fair Ratio

What is 22UA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

22UA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 22UA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 22UA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF83.01
CHF104.28
+25.6%
21.5%CHF154.84CHF80.86n/a17
May ’25CHF80.78
CHF104.36
+29.2%
20.7%CHF154.20CHF81.14n/a18
Apr ’25n/a
CHF105.76
0%
23.6%CHF168.60CHF80.66n/a18
Mar ’25CHF78.97
CHF111.20
+40.8%
22.5%CHF165.26CHF86.95n/a17
Feb ’25CHF82.57
CHF109.46
+32.6%
22.4%CHF161.50CHF84.97n/a16
Jan ’25n/a
CHF113.39
0%
21.0%CHF158.94CHF85.88n/a16
Dec ’24CHF87.65
CHF117.09
+33.6%
23.0%CHF172.94CHF86.18n/a17
Nov ’24n/a
CHF126.54
0%
23.1%CHF175.48CHF92.43n/a17
Oct ’24n/a
CHF133.80
0%
22.9%CHF180.14CHF90.81n/a16
Sep ’24n/a
CHF136.90
0%
26.1%CHF218.68CHF87.10n/a17
Aug ’24n/a
CHF141.05
0%
24.7%CHF218.68CHF94.81n/a17
Jul ’24n/a
CHF148.65
0%
23.1%CHF223.32CHF96.82n/a16
Jun ’24n/a
CHF146.01
0%
23.4%CHF222.46CHF96.45n/a17
May ’24n/a
CHF159.77
0%
23.7%CHF235.98CHF114.71CHF80.7817
Apr ’24n/a
CHF168.27
0%
22.2%CHF238.15CHF119.64n/a16
Mar ’24n/a
CHF191.64
0%
23.4%CHF276.48CHF131.37CHF78.9715
Feb ’24n/a
CHF192.61
0%
23.5%CHF278.08CHF132.58CHF82.5715
Jan ’24n/a
CHF198.61
0%
23.2%CHF305.53CHF141.84n/a15
Dec ’23n/a
CHF200.71
0%
22.4%CHF304.11CHF141.90CHF87.6516
Nov ’23n/a
CHF209.75
0%
24.6%CHF314.44CHF132.03n/a16
Oct ’23n/a
CHF205.69
0%
22.8%CHF314.27CHF150.86n/a16
Sep ’23n/a
CHF216.12
0%
26.1%CHF352.58CHF155.52n/a16
Aug ’23n/a
CHF220.08
0%
26.1%CHF336.17CHF155.20n/a15
Jul ’23n/a
CHF230.52
0%
25.3%CHF345.00CHF159.28n/a15
Jun ’23n/a
CHF229.98
0%
25.6%CHF340.75CHF163.47n/a14
May ’23n/a
CHF232.29
0%
26.0%CHF337.97CHF153.75n/a16

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.